 |
IDEA Collider: Innovation & Asymmetric Learning in PharmaAuthor: IDEA Pharma, SAI MedPartners
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma & Head of Strategy and Thought Leadership at SAI MedPartners, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace othersand what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * Whats broken in traditional innovation modelsand how do we fix it? Listen and subscribe on all major platforms. Language: en Genres: Business, Life Sciences, Marketing, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
Scaling CAR-T for Autoimmune Disease: Warner Biddle on Kyverna’s Breakthrough Strategy
Episode 12
Thursday, 9 April, 2026
In this episode of the IDEA Collider, host Mike Rea sits down with Warner Biddle, CEO of Kyverna Therapeutics, to explore how CAR-T cell therapy is expanding beyond oncology into autoimmune disease—and what it takes to scale one of the most complex innovations in modern medicine. Warner shares insights from his career across large pharma and biotech, breaking down why cell therapy requires a fundamentally different operating model—one that tightly integrates manufacturing, clinical execution, and commercialization. The conversation dives into how Kyverna is advancing CAR-T therapies for neuroimmunology indications, including stiff person syndrome (SPS), myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, while preparing its first Biologics License Application (BLA). They also unpack the broader cell therapy ecosystem, from improving hospital capacity and enabling outpatient treatment to evolving FDA regulatory pathways, CMC guidance, and REMS simplification—all critical to making CAR-T more accessible and scalable. Warner emphasizes that success in this space depends on trust-driven leadership, speed, and a willingness to embrace risk, while also highlighting the growing global competition—particularly from China—as a catalyst for faster innovation. Episode Timestamps 00:00 – Introduction to CAR-T and the future of autoimmune disease treatment 00:18 – Meet Warner Biddle and his journey across pharma and biotech 01:26 – Building a culture of innovation, trust, and speed 02:45 – Why cell therapy is fundamentally different from traditional drugs 03:57 – Ecosystem shifts: access, infrastructure, and outpatient care 06:03 – FDA tailwinds: CMC guidance, REMS changes, and regulatory momentum 07:24 – Kyverna’s strategy and rapid progress in stiff person syndrome (SPS) 09:04 – Manufacturing challenges and scaling CAR-T production 10:25 – Commercializing one-time therapies in a traditional pharma model 11:47 – Clinical impact of CAR-T in autoimmune diseases 13:32 – Investor momentum and biotech market dynamics 14:13 – Leadership principles: trust, urgency, and decision-making 18:33 – Scaling biotech while maintaining agility 20:56 – Expanding access: bringing CAR-T to community settings 23:24 – China’s accelerating innovation in cell therapy 26:18 – 2026 milestones and Kyverna’s pipeline outlook 29:43 – Closing thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Warner Biddle; LinkedIn: https://www.linkedin.com/in/warnerbiddle/ Website: https://kyvernatx.com/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ & https://www.sai-med.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/
